You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

ACTHAR GEL (AUTOINJECTOR) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Acthar Gel (autoinjector), and what generic alternatives are available?

Acthar Gel (autoinjector) is a drug marketed by Mallinckrodt Ard and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in ACTHAR GEL (AUTOINJECTOR) is corticotropin. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the corticotropin profile page.

DrugPatentWatch® Generic Entry Outlook for Acthar Gel (autoinjector)

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ACTHAR GEL (AUTOINJECTOR)?
  • What are the global sales for ACTHAR GEL (AUTOINJECTOR)?
  • What is Average Wholesale Price for ACTHAR GEL (AUTOINJECTOR)?
Summary for ACTHAR GEL (AUTOINJECTOR)
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:ACTHAR GEL (AUTOINJECTOR) at DailyMed
Drug patent expirations by year for ACTHAR GEL (AUTOINJECTOR)
Pharmacology for ACTHAR GEL (AUTOINJECTOR)

US Patents and Regulatory Information for ACTHAR GEL (AUTOINJECTOR)

ACTHAR GEL (AUTOINJECTOR) is protected by three US patents.

Patents protecting ACTHAR GEL (AUTOINJECTOR)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Ard ACTHAR GEL (AUTOINJECTOR) corticotropin INJECTABLE;INJECTION 008372-003 Feb 29, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mallinckrodt Ard ACTHAR GEL (AUTOINJECTOR) corticotropin INJECTABLE;INJECTION 008372-004 Feb 29, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.